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Tha regulation of tissue kallikr¢in activity by plasma serine proteina~ inhibitors (rerpins) was investigated by me, aBating the ar,~o¢iation ram 
constants of six tiuue-kaliikrein family m¢ml~r= isolated from the rat submandibular gland, with rat kallikrein-bindin$ protein (rKBP) and 
= i-protelnas~ inhibitor (¢zl.Pl), Both these s~rpins inhibited kallikreins rK2, rK7, rgg, rK9 and rK lO t with association rate constant,= in the lO~-I0" 
M" ',s" range, whereas only 'true' tissue kallikrcin rK I was not ~u__,~_ptible to¢i-Pl. This r~ults in slow inhibition ofrK l  by plasma =mrpins, which 
could =plain why this kallikr¢in is the ony mem~r of the gent family identified so far that induc4~ a transient d=¢rP.~m in blood pr~'r, zun= when 
injured in minute amounts into the circulation, 
Kallikrcin; Serpin; Protcinuse inhibitor: Kallikr¢in,binding protein 
I. INTRODUCTION 
The kallikrcin multigene family in the rat. designated 
RNOKLKx [l]. includes at l~ast 13 re=tubers [2], whose 
six protein products have now been clearly identified 
and correlated with their respective genes [3]. These 
proteins all have proteolytic activity, but their biological 
functions remain for the most part unknown. They are 
also structurally closely related, but recent data have 
shown that they possess different substrat¢ specificities 
[4--6] and tissue distributions [7.8]. indicating that they 
may be involved in physiological processes other than 
those depending on the release of kinins from kinino. 
gens, Rat tissue kallikreins also have different sus~pti- 
bil it i~ to heterologous inhibitors [3], which suggests 
that, physiologically, each one may be specifically regu- 
latcd. 
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'Kallikr¢ins are abbreviated according tothe: rules defined at the Gene 
Nomenclature Workshop during the Kinin'91 m~ating held in Mu- 
aS=h, September 8-14, 1991 [1], The most ~mmon ames in use until 
reentry were: ti~ue kaiiikreln, tonin, proteinase A or kalii-krein k?, 
kallikreln ktl. SEN or KLP-$3, antigen T or kallikrein kl0 or T.kini. 
nogenat¢, for rKI, rg2, rK'/, rKg, rR9 and rKl0. r~pcctively [l], 
Kallikrein-binding proteins (KEIP), which are struc- 
turally related to inhibitors of the serpin family, have 
rec¢ntly b~n found in human and rat pla=ma [9-12] but 
their pr=ise physiologi~l importune remains to b¢ 
elucidated. Rat KBP is not a potent or spc=ifi= plasma 
inhibitor of the "true' tissue kallikrein rKl [10]. which 
agre=s with the kininogenase activity of  this proteinase 
in plasma. However there is no information as to the 
¢ff=ts of plasma proteinase inhibitors on other mem- 
bers of  the tissue kallikrein family. None o f  these pro- 
t¢inases has vasoactive properties comparable to those 
of rKl. This could be due to rapid inhibition by plasma 
proteinase inhibitors and especially by serpins. We have 
therefore examined the kin=tics of  inhibition of  six 
members of  the rat tissue kallikrein family by homolo- 
gous KBP and ¢.l-PI, 
2. MATERIALS AND METHODS 
2.1. En:~,mes 
Rat tism. kallikreins rK I, rK2, rKT, rKg. rKP. rK IO were purified 
from submandibular gland homogenat~ as described previously [4-6], 
Bovine trypsin wa~ purchar, cd from Bochrlnger. 
2.2. 'dub~rratez 
The sub~trat¢ with intramolc¢ularly quenched f luor~n~ Abz- 
Phe-Arg.S~r-Ara.EDDnp was a gift from Dr. E, Prude (Ese.ola Pau- 
lista, Sue Paulo, Brazil), Z.Phg-Ars-MCA was from Baehem and 
Tos-Arg.OM= from Siiffna, 
2.3. tnhibitors 
Rat =l-Pl was purified from inflammato~ ~rum by thiol disulfide 
interchange [I 3j and CTnacron blue chromaioSf~al~/iy io remove ~t-dn'i 
albumin [14], rKBP was purilied as d~ribcd pr=viomsly [10], Aprot- 
inin was purcha,~d from Bo~hringer. 
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2,4, Ttu, atiuns 
Bovine trypsin was first titrated using p,nitro~hcnyl.p'-lemnidino- 
benzo;nc us described by Chat~ attd Shaw 115]. This ~axyme w~s tl~n 
u~d to determine the r=tetive site con~ntration f all inhibito~, i e, 
aprotinin, rat Ktap and rat ~I-PI, Rat KflP and aI-Pi were prepared 
ai stock tmlutions o1" 14/~M and 21 #M. ~speetively, Aprotinin was 
u~ed as an active site titrant for all kailikrcin,= except rK2 and rKg, 
which were liltaled with pNPGB [6]. Kallikreins were assayed at 30'C 
in 0.1M Tris-HCI buffer pH 8.5, I mM EDTA, whereas trypsin was 
assayed in 0A M Tris.HCI pH B,0, $0 mM calcium chloride, All other 
experimental conditions were as d¢~a:ribcd previously [16]. 
2.5, l~atr rruutants for asxociatim~ 
Rate constant,t for atn~:mtion (k.0 were monitored under ~mcond 
order conditions by allowinll ~uimolar con~ntratiom of protcina~ 
and inhibitor to react for various periods I~fore addinl~ subsmtte -nd 
immediately re~:ordinil to r~tiduat activity, lndMdual con~ntrations 
of rcactunts arc given in Table t. The final con~ntrations of pro- 
tcinasca nd inhibitors were in tt~ 10-~-I0 "' molar range for kalli. 
kreins and around I0"" molar for trypsin, All protcinurcs mixtures 
were incubated for 2-30 rain before adding the appropriate substrate. 
Under s=:ond order conditions, the intellratcd equation of asga:intion 
is: 
l i e  = k.~ ' t "," I IEo 
where Eo is th¢ total enzyme concentration, and E the frec en;~mc 
concentration at time t, Plots of l ie  versus time arc l iner with a dope 
corr~pondinll to k,,~ [171 provided the reverse reaction is negligible, 
The rgl-ctI-Pl interaction was aim m~surcd under p.~udo-flrst 
order conditions, using a tc,~nty fold molar excess of inhibitor (0,lit 
aM) over en~me (9 nM). Other experimental conditions were as 
~for¢. 
I~mily is of physiological relevance has not bc~n investi- 
gated so far. We therefore determined the rate constants 
of association of rat KBP and rat ~I-PI with rat tissue 
kallikreins rKl, rK2, rKT, rKg, rK9 and rKl0, and 
bovine trypsin, as a first step in a study of the physiolog- 
ical rclevan¢¢ of rKBP towards tissue kallikreins. 
R~ctive site titrated inhibitors and kallikreins were 
used at 1:1 molar ratio to determine association rate 
constants. Though the mechanism of inhibition by rat 
KBP is not known, it seems reasonable to a .ume that 
it is similar to that of ctl-PI, which is structurally re. 
lated, and belongs to the same family. This agrees with 
the hct that the reaction with KBP follows second order 
kincti~ almost to completion, and that the binding to 
ti~u¢ kallikrein r~ults in the formation of SDS-stable 
complexes [9], both results indicating a tight complex 
between the proteinase and its serpin inhibitor. The 
extreme stability of these complexes, prevents accurate 
determination of K~ values [28]. Association rate con- 
stares (/¢o.) therefore are the most representative kinetic 
parameters describing proteinase-serpin interactions. 
Table 1 
Association rate constants (h,,~ for the interaction ~twcen al-Pl or 






3, RESULTS AND DISCUSSION 
Previous studies era the kinin-releasin$ properties of 
rat kallikrein gone family enzymes have shown that 
rKl. but none of the other kallikrein family members, 
could induce a transient decrease in the blood pressure 
of ancsth~ized rats upon injection of amounts as small 
as 1 #g into the circulation [16]. Kallikrein rKl0. how. 
ever, releases bradykiain from purified rat high-M,-ki- 
nininosen in vitro [18] (Outman et al., unpublished re- 
suits). The failure of rKlO to release kinin in rive when 
used under the sam~ experimental conditions as rKl 
[16], could be because this proteinase is inactivated 
faster than is rKl. Only circulating autoantibodics [19] 
and al-PI in human serum [20] have been reported to 
modulate kailikrein activity, in addition to the recently 
described kallikrein-binding protein [9-12]. Sequence 
data have shown that this KBP, which is a negative 
marker of inflammation i the rat, corr~ponds to rat 
thyroid hormone-regulated protein [21], growth 
hormone-regulated proteinase inhibitor, also reported 
as SPI-2 [22-24], and could be the rat homologu¢ of 
mouse contrapsin [25]. Human kallikrcin-bindin$ pro- 
tein appears to be related to, but different from protein 
C inhibitor, apoly-~ai~t h~ar in -d~dem inhibi~or of 
serine proteinases [26,27], 
Whether or not the modulation of tissue kallikrcin 
activity by rKBP and related inhibitors of the serpin 
Trypsin Z-Phe*ArlI-MCA 
(3.5,10" M) (1.2.10 "~ M) 
{3,5'10"" M) 
(6,6 ~ l)10* 
(1.2 ± 0,2)10' 
rK ! Z-Phe-Arg-MCA 
(4,5.10"" M) (1.2.10 "~ M) 
(43'10"" M] 
no inhibition (2.5:1:0,6)10 x 
rK'l Z*Phe.Ars-MCA 
($,5,10"" M) (2,5.I0"* M) 
(6.6.10 "~ M) 
(6,1 • 0,4)10' 
(5 ± 0,8)10' 
rK l~ Z-Pha.Arg-MCA 
(2,10 "I M) (1.6.10 "~ M) 
(2., I0 "~ M) 
(1.1 ± 0,1]10' 
(1.7 ± 0,3)10' 
rK I0 ~.Phe.Arg-MCA 
(5,],I0"" M) (23,10" M) 
(I.7.I0 "~ M) 
(1.2 ± 0,3)i0 ~ 
(3.7 ± 03)10 ~ 
rK ~- Abz.Ph¢-Arg- 
Ser.Ars. 
EDDNP 
(I~.6.10 "j M) (6.10 "v M) (1.2 ± 0,4)10 ~ 
(I.7, I0 "~ M] (9.8 ± 1)10 ~ 
rK9 Tos.Arg.OMe 
(2.?.I0"" M) (2,10 "~ M) 
(3.7.10"* M) • 
(2.1 ± 0,?)10 ~ 
(8 ± 0.6)10 ~ 
Experiments were ~rr i~  out at 30°C, in 0,1 M Tris.HC[ buffer pH 
8,5, I mM EDTA for all kallikmins and in 0, I M Tris.HCl buffer, pH 
8,0, 50 mM calcium chlorid~ for trypsin, R~sults (M "~.,r~) arc the 
m~ans of at least two experiments. 
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The nmul~ in Table I show that all the prot~w wm'~ 
inhibited, though not rapidly, by both inhibitore, with 
the notable x~ptinn of rKl, whkh is not stm~eptibl~ 
to ~I-PI. 
The lack of rK! inhibition by (xi-Pl, was confirmed 
rains under p~udo-fint ord~r conditions with respect 
to proteine.~ to attmnpt to in t~n~ the rat, of inhibi- 
tion. Even with the twenty.fold molar q,x~m~t of ~I-Pl 
over rK! used, then: w~ no sis~ilkant inhibition of 
rKl.  
TI~ rgslatangg ofrK l  to inhibition by ~tl-Pl may be 
explained by its subatrate SlX:Cifi¢ity, which differs from 
that of other rat I~d~ and of human tissue kal- 
likrcin, hK2[l], rKI relea.u~ brndykinin from rat kinin- 
oBr-'m after gl~avase at two Pi Ar 8 sites (nomenclature 
of S~hcchtcr and lkrs~r [29]), whereas its human hom- 
olo~c, which m inhibited by ~i-Pi. thoush rather 
slowly, elmves kininosen after M~t and Arg t~idu~ to 
release LT~-bradykinin. The susceptible bond (Pl-Pl ' )  
in both rat and human ~I.Pl is Met-Set [30]. The m- 
s ~  Sl~:ifF.'ity of mt kallikn:in rKI  gompan:d to 
that of other members of the 8~ne family [31, misht 
tender it unable to accommodate a Pi Met t~idue, and 
prevent it from bein 8 inhibited by this inhibitor. In 
gontra~t to ~tl-Pl, the sttu:eptible bond in rK l~ i.~ 
thousht to be Ly~Ser [21,22], which b more favo.rabh: 
for intera~on with tryl~n-related proteina:t~. 
Another charagtemtio feature of kallikre;n inhibition 
by serpin inhibitors is the rather slow and similtr mt~ 
at whkh the binding o~ul~ whatever the kallikrgin 
used. The rate constants valu~ arc all within about one 
order ofma~paimde, and are about I00 times lower tlum 
that for bovine U'y~io. 
This low rate of binding rab~ the qu,mtion of thg 
biological relevance of tl~ phenon~,.'non. The inhibition 
of k~llikreins by ~rpin~ in the gi~g,lation ~hould follow 
i~eudo tint order kinctig~, sin~e the inhibitor~ are in 
larse molar cxgg~ over pro te in .  Under theag condi- 
tions thc half time for a.~ogiation b:
t~s : 0.693 1 k~lo] 
11~e plasma phT~iolo~igal con~ntratiom [I~] ofezl-Pl 
(.fO-70~M) and rKBP (6--8/~M) (Chao, J., unpublished 
rm.lt~) 8ivc p~udo first order gon~tant~ (k~[la]) of O.I 
to i :~-i for thong kallikreins whieh am inhibited by both 
inhlbitot~. The half-life of ~t ion  in plasma would 
therefore be l to 10 s, and about 40 s for rKi, which 
may be enoush to modulate kalliktein aetiviti¢~ but not 
to ensure ~ t e  control of these aetiviti~ [31]. With 
re~trds to rg i0  which h~ kininosenase propt'rti~ in 
vitro but not in vivo, th~ half-life for association with 
scrpins (essentially 0tl-Pi) would be about I s, which b 
~ ~ .  ~. .  ,h._ ,~  ~tc~. . . .~ . . .~  _mr K..~P 
inhibit rKl. This difference is even more sisnifi~mt 
durin~ inflammation, since ~i-Pi concentration i . 
cma.~s under these conditions, while KBP decr~as~ 
[10], Nev0nlw.le~ the rate at which rKl0 is inhibited by 
mpin  inhibitzn ceanot ensure inmtediate and ¢omplgte 
gontrol of its agtivit~; thua the ~ of other poX'at 
and thua far unidentified n:ulatin~ inh~tor(s) lm~ 
ventin$ rKIO but not rKI from bein S a p h ~  
kinin.~.lmsin~ protehmae cannot be dimimu:d. 
The protgh~ of the thra~ kallikrein family have 
diffmnt substrate Slx¢iftciti~ [4-6]. This is probably 
due to their ~ subs~te bindin8 site, ~ mu-  
fen a SlX~eity to subsit~s other than St. whkh l~'fgr- 
carnally ac~m~tes  Ag 8 rmidt~t in most tmue kal- 
likn~im. This explains why sevm'~ mcmhen of  the kal- 
likrein family, which do not exhibit k in in -~ B a~- 
tiviti~, may have s ~  activiti~ in otlgr thuga or 
f~a~-~tions where ~ happen to Ix: prc~cnt [7]. TI~ rat~ 
of  KBP and ~i-Pl bindin~ to ti~uc ~ found 
here sa~4~tt.% that ~ inhibitors gall be p h ~  
cally reiovant in nmintaioin~ the activity of ugh  pro. 
teinar~ within a range of mn~ntration m~tnixuibk 
with their biolos~l function [31]. The fagt that ai~nta- 
n~ou~ly hypertensive rata have low kvel of giggulatin8 
KBP abo su~gg:tta hat the modulation of rKi agtivit~ 
by this inhibitor is biolo~mlly si~nifgant [32]. 
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